Contextualised cost-effectiveness of a complete set of interventions—ranking of 13 maternal and child health, 19 mental and neurological and 29 cardiovascular interventions by their respective ICER
| Condition | Interventions | Annual cost (US$)* | DALYs averted | ICER (US$/DALY) | Rank |
| Major depressive disorder | Older antidepressants (TCA) | 15 935 000 | 24 300 | D | – |
| Newer antidepressants (SSRI) | 18 542 000 | 29 100 | 636 | 17 | |
| Psychotherapy | 68 138 000 | 29 100 | D | – | |
| Older antidepressants (TCA) and psychotherapy | 69 632 000 | 34 100 | D | – | |
| Newer antidepressants (SSRI) and psychotherapy | 71 402 000 | 40 600 | 4621 | ||
| Major depressive disorder | Maintenance: Older antidepressants (TCA) and psychotherapy | 62 081 000 | 58 900 | 1054 | 18 |
| Maintenance: Newer antidepressants (SSRI) and psychotherapy | 65 789 000 | 62 200 | 1135 | 19 | |
| Schizophrenia | Typical antipsychotics | 23 639 000 | 4900 | D | – |
| Atypical antipsychotics | 23 635 000 | 6000 | D | – | |
| Typical antipsychotics+psychosocial treatment | 25 058 000 | 9000 | D | – | |
| Atypical antipsychotics+psychosocial treatment | 26 252 000 | 10 600 | 2465 | 24 | |
| Case id+management: Typical antipsychotics and psychosocial treatment | 30 097 000 | 11 100 | D | – | |
| Case id+management: Atypical antipsychotics and psychosocial treatment | 31 290 000 | 11 600 | 5211 | 28 | |
| Bipolar affective disorder | Older mood stabiliser (Lithium) | 28 560 000 | 17 600 | 1627 | 22 |
| Older mood stabiliser (Lithium) and psychosocial treatment | 33 045 000 | 19 300 | 2518 | 25 | |
| Newer mood stabiliser (Valproate) | 31 913 000 | 18 600 | D | – | |
| Newer mood stabiliser (Valproate) and psychosocial treatment | 36 418 000 | 20 500 | 2819 | 26 | |
| Epilepsy | Older antiepileptic treatment (Phenobarbital) | 30 874 000 | 68 900 | 448 | 16 |
| Newer antiepileptic treatment (Carbamazepine) | 67 170 000 | 68 900 | HIGH | 31 | |
| Acute ischaemic heart disease | ACE inhibitor | 3 082 000 | 300 | D | – |
| Beta-blocker | 3 084 000 | 600 | D | – | |
| ASA | 3 087 000 | 1000 | D | – | |
| Streptokinase | 3 662 000 | 1200 | D | – | |
| ASA+clopidogrel | 3 094 000 | 1400 | D | – | |
| ASA+streptokinase | 3 692 000 | 2100 | D | – | |
| ASA+streptokinase+ACE inhibitor+beta-blocker | 3 790 000 | 2100 | D | – | |
| ASA+streptokinase+ACE inhibitor | 3 700 000 | 2400 | 1544 | 21 | |
| Primary PCI | 10 755 000 | 2700 | D | – | |
| ASA+clopidogrel+PCI | 11 032 000 | 4000 | 4529 | 29 | |
| Post-acute IHD | Statin | 3 552 000 | 300 | D | – |
| Beta-blocker | 3 281 000 | 500 | D | – | |
| ACE inhibitor | 3 306 000 | 500 | D | – | |
| ASA+beta-blocker | 3 337 000 | 700 | D | – | |
| ASA+beta-blocker+statin | 3 659 000 | 1000 | D | – | |
| ASA+beta-blocker+statin+ACE inhibitor | 3 736 000 | 1600 | 2400 | 23 | |
| Acute ischaemic stroke | ASA | 3 282 000 | 100 | 52 102 | 30 |
| Post-acute stroke | ACE inhibitor | 3 730 000 | 900 | D | – |
| ASA | 3 707 000 | 1000 | D | – | |
| ASA+statin | 4 414 000 | 2400 | D | – | |
| ASA+statin+ACE inhibitor | 4 518 000 | 3300 | 1376 | 20 | |
| Primary prevention of CVD | Individual cholesterol treatment((tot. chol.>6.2 mmol/L) | 6 059 000 | 8800 | D | – |
| Individual cholesterol treatment (tot. chol. >5.7 mmol/L) | 13 778 000 | 19 100 | D | – | |
| Individual hypertension treatment (SBP>160 mm Hg) | 9 510 000 | 98 900 | D | – | |
| Combination drug treatment for absolute risk of CVD>35% | 9 315 000 | 125 700 | 74 | 5 | |
| Individual hypertension treatment (SBP >140 mm Hg) | 25 196 000 | 125 700 | D | – | |
| Combination drug treatment for absolute risk of CVD>25% | 12 753 000 | 128 000 | D | – | |
| Combination drug treatment for absolute risk of CVD>15% | 18 696 000 | 153 900 | 333 | 14 | |
| Combination drug treatment for absolute risk of CVD>5% | 34 835 000 | 190 400 | 442 | 15 | |
| Neonatal disorders | Neonatal resuscitation (institutional) | 353 000 | 54 700 | 6 | 1 |
| Neonatal disorders | Kangaroo mother care | 287 000 | 36 700 | 8 | 2 |
| Neonatal disorders | Newborn sepsis—Injectable antibiotics | 906 000 | 52 100 | 17 | 3 |
| Maternal/neonatal disorders | Antibiotics for pPRoM | 591 000 | 8500 | 69 | 4 |
| Neonatal disorders | Antenatal corticosteroids for preterm labour | 837 000 | 8600 | 98 | 6 |
| Maternal disorders | Safe abortion | 737 000 | 6800 | 108 | 7 |
| Maternal/neonatal disorders | Management of pre-eclampsia and eclampsia | 519 000 | 4800 | 108 | 7 |
| Neonatal disorders | Induction of labour (beyond 41 weeks) | 393 000 | 2600 | 152 | 9 |
| Maternal/neonatal disorders | Tetanus toxoid (pregnant women) | 2 688 000 | 16 000 | 168 | 10 |
| Maternal disorders | Maternal sepsis case management | 1 151 000 | 5200 | 220 | 11 |
| Maternal/neonatal disorders | Syphilis detection and treatment (pregnant women) | 1 522 000 | 6800 | 224 | 12 |
| Maternal/neonatal disorders | Active management of the third stage of labour | 1 617 000 | 6600 | 244 | 13 |
| Maternal/neonatal disorders | Calcium supplementation | 4 949 000 | 1600 | 3081 | 27 |
*2018 US$.
ACE, angiotensin-converting enzyme; ASA, acetylsalisylic acid; CVD, cardiovascular disease; ICER, incremental cost-effectiveness rate; IHD, ischemic heart disease; PCI, percutaneous coronary intervention; pPRoM, preterm premature rupture of membrane; SBP, systolic blood pressure; SSRI, selective serotonin reuptake inhibitors; TCA, tricyclic antidepressants.